BACKGROUND: The purpose of this study was to report long-term outcomes for a large cohort of patients with head and neck squamous cell carcinoma (HNSCC) who underwent stereotactic body radiotherapy (SBRT) reirradiation. METHODS: From 2002 to 2011, 85 patients with previously irradiated HNSCC were treated with SBRT to 94 lesions. Some underwent surgery (29%), and many were treated with induction, concurrent, and/or adjuvant chemotherapy or biologic therapy (70%). RESULTS: Reirradiation occurred at a median interval from initial radiotherapy (RT) of 32 months. Median follow-up for survivors was 17.3 months. Two-year Kaplan-Meier estimates of overall survival (OS) and locoregional control for patients and lesions treated with curative intent were 24% and 28%, respectively. Interval from initial RT to SBRT of 2 years or more was associated with improved OS (p = .019). Five patients had grade 3 or higher late toxicity (5.9%). CONCLUSION: SBRT reirradiation results in limited toxicity. Further research is needed to refine optimal roles for SBRT and intensity-modulated radiotherapy (IMRT) reirradiation.
BACKGROUND: The purpose of this study was to report long-term outcomes for a large cohort of patients with head and neck squamous cell carcinoma (HNSCC) who underwent stereotactic body radiotherapy (SBRT) reirradiation. METHODS: From 2002 to 2011, 85 patients with previously irradiated HNSCC were treated with SBRT to 94 lesions. Some underwent surgery (29%), and many were treated with induction, concurrent, and/or adjuvant chemotherapy or biologic therapy (70%). RESULTS: Reirradiation occurred at a median interval from initial radiotherapy (RT) of 32 months. Median follow-up for survivors was 17.3 months. Two-year Kaplan-Meier estimates of overall survival (OS) and locoregional control for patients and lesions treated with curative intent were 24% and 28%, respectively. Interval from initial RT to SBRT of 2 years or more was associated with improved OS (p = .019). Five patients had grade 3 or higher late toxicity (5.9%). CONCLUSION: SBRT reirradiation results in limited toxicity. Further research is needed to refine optimal roles for SBRT and intensity-modulated radiotherapy (IMRT) reirradiation.
Authors: Megan Morisada; Ellen C Moore; Rachel Hodge; Jay Friedman; Harrison A Cash; James W Hodge; James B Mitchell; Clint T Allen Journal: Oral Oncol Date: 2017-06-10 Impact factor: 5.337
Authors: Ayman Oweida; Andy Phan; Benjamin Vancourt; Tyler Robin; Mohammad K Hararah; Shilpa Bhatia; Dallin Milner; Shelby Lennon; Laura Pike; David Raben; Bryan Haugen; Nikita Pozdeyev; Rebecca Schweppe; Sana D Karam Journal: Thyroid Date: 2018-06 Impact factor: 6.568
Authors: Alexander F Bagley; Adam S Garden; Jay P Reddy; Amy C Moreno; Steven J Frank; David I Rosenthal; William H Morrison; Gary Brandon Gunn; Clifton D Fuller; Shalin J Shah; Renata Ferrarotto; Erich M Sturgis; Neil D Gross; Jack Phan Journal: Head Neck Date: 2020-08-09 Impact factor: 3.147
Authors: Arya Amini; Jessica D McDermott; Gregory Gan; Shilpa Bhatia; Whitney Sumner; Christine M Fisher; Antonio Jimeno; Daniel W Bowles; David Raben; Sana D Karam Journal: Front Oncol Date: 2014-10-08 Impact factor: 6.244
Authors: Leonard Kim; Stephanie Markovina; Samantha J Van Nest; Subarna Eisaman; Lakshmi Santanam; Julie M Sullivan; Michael Dominello; Michael C Joiner; Jay Burmeister Journal: J Appl Clin Med Phys Date: 2019-05-25 Impact factor: 2.102
Authors: Muhammad Shahid Iqbal; Nick West; Neil Richmond; Josef Kovarik; Isabel Gray; Nick Willis; David Morgan; Gozde Yazici; Mustafa Cengiz; Vinidh Paleri; Charles Kelly Journal: Br J Radiol Date: 2020-09-24 Impact factor: 3.039
Authors: Luke Stanisce; Yekaterina Koshkareva; Qianyi Xu; Ashish Patel; Christian Squillante; Nadir Ahmad; Kumar Rajagopalan; Gregory J Kubicek Journal: Technol Cancer Res Treat Date: 2018-01-01